ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Eight Minority CCP Awards Confirmed, Four More Coming; General Motors Winners Named

June 15, 1990

Panel Debates Whether DCIS Needs A New Name

September 25, 2009

Prevention Facility For Intramural Research Approved, Also Would Involve Academic Investigators

November 1, 1991

In Brief: Newell Denies He’s Leaving For Job On West Coast, Says He Is A “Free Agent”

November 4, 1977

NCI Resources, Services Available For Cancer Research

June 7, 1996

Help Wanted: Varmus Irked by Having to Fill Jobs With Salaries NCI Can’t Afford to Pay

July 6, 2012